Significance of early aminotransferase elevation after liver transplantation

Hugo R. Rosen, Paul Martin, John Goss, John Donovan, Judy Melinek, Steve Rudich, David K. Imagawa, Milan Kinkhabwala, Philip Seu, Ronald W. Busuttil, Christopher R. Shackleton

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background. We retrospectively reviewed 213 consecutive patients who received their first liver allograft between January 1 and December 31, 1993, in order to study the impact of ischemia/preservation/reperfusion injury (IPRI) on patient and graft outcome. Methods. The extent of IPRI was assessed by the peak value of aspartate aminotransferase (AST(max)) observed within the first 72 hr after transplant. For the purpose of univariate analysis, categorical classification of recipients was done based upon AST(max) as follows: group 1, AST(max)<600 U/L (n=46); group 2, AST(max)=600-2000 U/L (n=97); group 3, AST(max)>2000-5000 U/L (n=50), and group 4, AST(max)>5000 U/L (n=17). For multivariate analysis, stepwise Cox regression was performed with age, AST(max) and United Network for Organ Sharing (UNOS) status as covariates. Results. Groups were comparable with respect to age, UNOS status at the time of transplantation, and diagnostic case mix. Median follow-up was 644 days. The overall incidence of primary graft nonfunction (PNF) was 7.6%. PNF incidence was significantly correlated with the severity of IPRI (0%, 4%, 10%, and 41% for groups 1 to 4, respectively, P<0.0001), but this impact was confined to the respective rates of retransplantation as early patient survival was unaffected. The 1-year survival of patients whose initial grafts manifested extreme IPRI (group 4) was significantly inferior to recipients in the three other groups (77%, 71%, 73%, and 52% for groups 1 to 4, respectively, P=0.03). This increased mortality was confined to patients who never achieved discharge from their initial hospitalization, with no significant differences between groups being detected in the survival of those patients who were discharged (84%, 80%, 85%, and 81% for groups 1 to 4, respectively, P=NS). Although overall 1-year graft survival was strongly correlated with the extent of IPRI (77%, 67%, 62%, and 41% for groups 1 to 4, respectively, P=0.001), this correlation was abolished when survival of grafts not lost to PNF was examined at 1 and 2 years. Stepwise Cox regression analysis confirmed the independent association between AST(max) and patient and graft survival. The long-term quality of allograft function as well as the incidence of chronic rejection and biliary complications were unrelated to the extent of IPRI. Conclusions. We conclude that: (1) patient survival is influenced by IPRI only when it is extreme (AST(max) >5000 U/L), provided parameters of graft function are used in conjunction with aminotransferase values to assess the need for prompt retransplantation; (2) short-term graft survival is proportional to the extent of IPRI, but grafts that are not lost to PNF have equivalent 1- and 2-year survival irrespective of the magnitude of IPRI; (3) 40% of grafts with extreme IPRI are lost to PNF, but the same proportion also provide long-term function; and (4) for surviving grafts, long-term biochemical function as well as the incidence of biliary complications and of chronic rejection are unrelated to the extent of IPRI.

Original languageEnglish (US)
Pages (from-to)68-72
Number of pages5
JournalTransplantation
Volume65
Issue number1
DOIs
StatePublished - Jan 15 1998
Externally publishedYes

Fingerprint

Transaminases
Liver Transplantation
Reperfusion Injury
Transplants
Incidence
Diagnosis-Related Groups
Graft Survival
Aspartate Aminotransferases
Allografts
Multivariate Analysis
Transplantation
Survival
Liver

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Rosen, H. R., Martin, P., Goss, J., Donovan, J., Melinek, J., Rudich, S., ... Shackleton, C. R. (1998). Significance of early aminotransferase elevation after liver transplantation. Transplantation, 65(1), 68-72. https://doi.org/10.1097/00007890-199801150-00013

Significance of early aminotransferase elevation after liver transplantation. / Rosen, Hugo R.; Martin, Paul; Goss, John; Donovan, John; Melinek, Judy; Rudich, Steve; Imagawa, David K.; Kinkhabwala, Milan; Seu, Philip; Busuttil, Ronald W.; Shackleton, Christopher R.

In: Transplantation, Vol. 65, No. 1, 15.01.1998, p. 68-72.

Research output: Contribution to journalArticle

Rosen, HR, Martin, P, Goss, J, Donovan, J, Melinek, J, Rudich, S, Imagawa, DK, Kinkhabwala, M, Seu, P, Busuttil, RW & Shackleton, CR 1998, 'Significance of early aminotransferase elevation after liver transplantation', Transplantation, vol. 65, no. 1, pp. 68-72. https://doi.org/10.1097/00007890-199801150-00013
Rosen HR, Martin P, Goss J, Donovan J, Melinek J, Rudich S et al. Significance of early aminotransferase elevation after liver transplantation. Transplantation. 1998 Jan 15;65(1):68-72. https://doi.org/10.1097/00007890-199801150-00013
Rosen, Hugo R. ; Martin, Paul ; Goss, John ; Donovan, John ; Melinek, Judy ; Rudich, Steve ; Imagawa, David K. ; Kinkhabwala, Milan ; Seu, Philip ; Busuttil, Ronald W. ; Shackleton, Christopher R. / Significance of early aminotransferase elevation after liver transplantation. In: Transplantation. 1998 ; Vol. 65, No. 1. pp. 68-72.
@article{0794e2aed9dc40e182004b9ca563b996,
title = "Significance of early aminotransferase elevation after liver transplantation",
abstract = "Background. We retrospectively reviewed 213 consecutive patients who received their first liver allograft between January 1 and December 31, 1993, in order to study the impact of ischemia/preservation/reperfusion injury (IPRI) on patient and graft outcome. Methods. The extent of IPRI was assessed by the peak value of aspartate aminotransferase (AST(max)) observed within the first 72 hr after transplant. For the purpose of univariate analysis, categorical classification of recipients was done based upon AST(max) as follows: group 1, AST(max)<600 U/L (n=46); group 2, AST(max)=600-2000 U/L (n=97); group 3, AST(max)>2000-5000 U/L (n=50), and group 4, AST(max)>5000 U/L (n=17). For multivariate analysis, stepwise Cox regression was performed with age, AST(max) and United Network for Organ Sharing (UNOS) status as covariates. Results. Groups were comparable with respect to age, UNOS status at the time of transplantation, and diagnostic case mix. Median follow-up was 644 days. The overall incidence of primary graft nonfunction (PNF) was 7.6{\%}. PNF incidence was significantly correlated with the severity of IPRI (0{\%}, 4{\%}, 10{\%}, and 41{\%} for groups 1 to 4, respectively, P<0.0001), but this impact was confined to the respective rates of retransplantation as early patient survival was unaffected. The 1-year survival of patients whose initial grafts manifested extreme IPRI (group 4) was significantly inferior to recipients in the three other groups (77{\%}, 71{\%}, 73{\%}, and 52{\%} for groups 1 to 4, respectively, P=0.03). This increased mortality was confined to patients who never achieved discharge from their initial hospitalization, with no significant differences between groups being detected in the survival of those patients who were discharged (84{\%}, 80{\%}, 85{\%}, and 81{\%} for groups 1 to 4, respectively, P=NS). Although overall 1-year graft survival was strongly correlated with the extent of IPRI (77{\%}, 67{\%}, 62{\%}, and 41{\%} for groups 1 to 4, respectively, P=0.001), this correlation was abolished when survival of grafts not lost to PNF was examined at 1 and 2 years. Stepwise Cox regression analysis confirmed the independent association between AST(max) and patient and graft survival. The long-term quality of allograft function as well as the incidence of chronic rejection and biliary complications were unrelated to the extent of IPRI. Conclusions. We conclude that: (1) patient survival is influenced by IPRI only when it is extreme (AST(max) >5000 U/L), provided parameters of graft function are used in conjunction with aminotransferase values to assess the need for prompt retransplantation; (2) short-term graft survival is proportional to the extent of IPRI, but grafts that are not lost to PNF have equivalent 1- and 2-year survival irrespective of the magnitude of IPRI; (3) 40{\%} of grafts with extreme IPRI are lost to PNF, but the same proportion also provide long-term function; and (4) for surviving grafts, long-term biochemical function as well as the incidence of biliary complications and of chronic rejection are unrelated to the extent of IPRI.",
author = "Rosen, {Hugo R.} and Paul Martin and John Goss and John Donovan and Judy Melinek and Steve Rudich and Imagawa, {David K.} and Milan Kinkhabwala and Philip Seu and Busuttil, {Ronald W.} and Shackleton, {Christopher R.}",
year = "1998",
month = "1",
day = "15",
doi = "10.1097/00007890-199801150-00013",
language = "English (US)",
volume = "65",
pages = "68--72",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Significance of early aminotransferase elevation after liver transplantation

AU - Rosen, Hugo R.

AU - Martin, Paul

AU - Goss, John

AU - Donovan, John

AU - Melinek, Judy

AU - Rudich, Steve

AU - Imagawa, David K.

AU - Kinkhabwala, Milan

AU - Seu, Philip

AU - Busuttil, Ronald W.

AU - Shackleton, Christopher R.

PY - 1998/1/15

Y1 - 1998/1/15

N2 - Background. We retrospectively reviewed 213 consecutive patients who received their first liver allograft between January 1 and December 31, 1993, in order to study the impact of ischemia/preservation/reperfusion injury (IPRI) on patient and graft outcome. Methods. The extent of IPRI was assessed by the peak value of aspartate aminotransferase (AST(max)) observed within the first 72 hr after transplant. For the purpose of univariate analysis, categorical classification of recipients was done based upon AST(max) as follows: group 1, AST(max)<600 U/L (n=46); group 2, AST(max)=600-2000 U/L (n=97); group 3, AST(max)>2000-5000 U/L (n=50), and group 4, AST(max)>5000 U/L (n=17). For multivariate analysis, stepwise Cox regression was performed with age, AST(max) and United Network for Organ Sharing (UNOS) status as covariates. Results. Groups were comparable with respect to age, UNOS status at the time of transplantation, and diagnostic case mix. Median follow-up was 644 days. The overall incidence of primary graft nonfunction (PNF) was 7.6%. PNF incidence was significantly correlated with the severity of IPRI (0%, 4%, 10%, and 41% for groups 1 to 4, respectively, P<0.0001), but this impact was confined to the respective rates of retransplantation as early patient survival was unaffected. The 1-year survival of patients whose initial grafts manifested extreme IPRI (group 4) was significantly inferior to recipients in the three other groups (77%, 71%, 73%, and 52% for groups 1 to 4, respectively, P=0.03). This increased mortality was confined to patients who never achieved discharge from their initial hospitalization, with no significant differences between groups being detected in the survival of those patients who were discharged (84%, 80%, 85%, and 81% for groups 1 to 4, respectively, P=NS). Although overall 1-year graft survival was strongly correlated with the extent of IPRI (77%, 67%, 62%, and 41% for groups 1 to 4, respectively, P=0.001), this correlation was abolished when survival of grafts not lost to PNF was examined at 1 and 2 years. Stepwise Cox regression analysis confirmed the independent association between AST(max) and patient and graft survival. The long-term quality of allograft function as well as the incidence of chronic rejection and biliary complications were unrelated to the extent of IPRI. Conclusions. We conclude that: (1) patient survival is influenced by IPRI only when it is extreme (AST(max) >5000 U/L), provided parameters of graft function are used in conjunction with aminotransferase values to assess the need for prompt retransplantation; (2) short-term graft survival is proportional to the extent of IPRI, but grafts that are not lost to PNF have equivalent 1- and 2-year survival irrespective of the magnitude of IPRI; (3) 40% of grafts with extreme IPRI are lost to PNF, but the same proportion also provide long-term function; and (4) for surviving grafts, long-term biochemical function as well as the incidence of biliary complications and of chronic rejection are unrelated to the extent of IPRI.

AB - Background. We retrospectively reviewed 213 consecutive patients who received their first liver allograft between January 1 and December 31, 1993, in order to study the impact of ischemia/preservation/reperfusion injury (IPRI) on patient and graft outcome. Methods. The extent of IPRI was assessed by the peak value of aspartate aminotransferase (AST(max)) observed within the first 72 hr after transplant. For the purpose of univariate analysis, categorical classification of recipients was done based upon AST(max) as follows: group 1, AST(max)<600 U/L (n=46); group 2, AST(max)=600-2000 U/L (n=97); group 3, AST(max)>2000-5000 U/L (n=50), and group 4, AST(max)>5000 U/L (n=17). For multivariate analysis, stepwise Cox regression was performed with age, AST(max) and United Network for Organ Sharing (UNOS) status as covariates. Results. Groups were comparable with respect to age, UNOS status at the time of transplantation, and diagnostic case mix. Median follow-up was 644 days. The overall incidence of primary graft nonfunction (PNF) was 7.6%. PNF incidence was significantly correlated with the severity of IPRI (0%, 4%, 10%, and 41% for groups 1 to 4, respectively, P<0.0001), but this impact was confined to the respective rates of retransplantation as early patient survival was unaffected. The 1-year survival of patients whose initial grafts manifested extreme IPRI (group 4) was significantly inferior to recipients in the three other groups (77%, 71%, 73%, and 52% for groups 1 to 4, respectively, P=0.03). This increased mortality was confined to patients who never achieved discharge from their initial hospitalization, with no significant differences between groups being detected in the survival of those patients who were discharged (84%, 80%, 85%, and 81% for groups 1 to 4, respectively, P=NS). Although overall 1-year graft survival was strongly correlated with the extent of IPRI (77%, 67%, 62%, and 41% for groups 1 to 4, respectively, P=0.001), this correlation was abolished when survival of grafts not lost to PNF was examined at 1 and 2 years. Stepwise Cox regression analysis confirmed the independent association between AST(max) and patient and graft survival. The long-term quality of allograft function as well as the incidence of chronic rejection and biliary complications were unrelated to the extent of IPRI. Conclusions. We conclude that: (1) patient survival is influenced by IPRI only when it is extreme (AST(max) >5000 U/L), provided parameters of graft function are used in conjunction with aminotransferase values to assess the need for prompt retransplantation; (2) short-term graft survival is proportional to the extent of IPRI, but grafts that are not lost to PNF have equivalent 1- and 2-year survival irrespective of the magnitude of IPRI; (3) 40% of grafts with extreme IPRI are lost to PNF, but the same proportion also provide long-term function; and (4) for surviving grafts, long-term biochemical function as well as the incidence of biliary complications and of chronic rejection are unrelated to the extent of IPRI.

UR - http://www.scopus.com/inward/record.url?scp=0031887802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031887802&partnerID=8YFLogxK

U2 - 10.1097/00007890-199801150-00013

DO - 10.1097/00007890-199801150-00013

M3 - Article

C2 - 9448146

AN - SCOPUS:0031887802

VL - 65

SP - 68

EP - 72

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -